Preserved T cell but attenuated antibody response in MS patients on fingolimod and ocrelizumab following 2nd and 3rd SARS-CoV-2 mRNA vaccine.

MULTIPLE SCLEROSIS JOURNAL(2023)

引用 2|浏览5
暂无评分
摘要
NCT05060354.
更多
查看译文
关键词
COVID-19,Multiple sclerosis,T cell response,disease modifying therapies,mRNA vaccine
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要